BARDA biothreat contract could bring $40M to Tetraphase

BARDA biothreat contract could bring $40M to Tetraphase

January 25, 2012

By Lori Valigra

Synthetic chemistry company Tetraphase Pharmaceuticals Inc. of Watertown could get $40 million from a federal contract to develop an antibiotic to potentially treat illnesses resulting from biological threats such as anthrax, tularemia or pestis, the company told Mass High Tech in an interview.